Docetaxel Seacross: Uses, Dosage & Side Effects
A taxane chemotherapy agent used to treat breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer
Docetaxel Seacross is a taxane-class chemotherapy medication containing docetaxel as its active ingredient. It is a 20 mg/ml concentrate for solution for intravenous infusion used to treat several major cancer types, including breast cancer, non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck. Docetaxel works by stabilizing microtubules and preventing cancer cells from dividing. It is always administered in a hospital or clinic setting under the supervision of oncology specialists. Premedication with corticosteroids is required before each cycle to reduce the risk of hypersensitivity reactions and fluid retention.
Quick Facts: Docetaxel Seacross
Key Takeaways
- Docetaxel Seacross is a taxane chemotherapy drug that works by stabilizing microtubules, preventing cancer cells from dividing and ultimately causing their death. It is one of the most widely used cytotoxic agents in modern oncology.
- It is approved for the treatment of breast cancer (adjuvant and metastatic), non-small cell lung cancer, metastatic castration-resistant prostate cancer, gastric adenocarcinoma, and head and neck squamous cell carcinoma.
- Premedication with oral corticosteroids (typically dexamethasone) is mandatory before each treatment cycle to reduce the incidence of fluid retention and hypersensitivity reactions.
- Neutropenia is the most common dose-limiting toxicity; blood counts must be monitored before each cycle, and treatment should not be administered if neutrophil counts are below 1,500 cells/mm³.
- Both men and women of reproductive potential must use effective contraception during treatment and for at least 6 months after the last dose. Docetaxel is embryotoxic and must not be used during pregnancy.
What Is Docetaxel Seacross and What Is It Used For?
Docetaxel Seacross contains the active substance docetaxel, a semisynthetic taxane derived from the needles of the European yew tree (Taxus baccata). Docetaxel belongs to the taxane family of antineoplastic agents, which also includes paclitaxel. The taxanes represent one of the most important classes of chemotherapy drugs developed in the past several decades and have transformed the treatment of multiple solid tumors. Docetaxel was first approved by the European Medicines Agency (EMA) in 1995 and by the U.S. Food and Drug Administration (FDA) in 1996, and it remains a cornerstone of modern oncology treatment protocols.
The mechanism of action of docetaxel is fundamentally different from many other chemotherapy agents. While most cytotoxic drugs work by damaging DNA or inhibiting DNA synthesis, docetaxel targets the microtubule system of the cell. Microtubules are dynamic protein structures composed of tubulin subunits that play essential roles in cell division, intracellular transport, and maintenance of cell shape. During normal cell division (mitosis), microtubules assemble and disassemble in a carefully regulated process to form the mitotic spindle, which separates the duplicated chromosomes into two daughter cells. Docetaxel promotes the assembly of tubulin into stable microtubules and, critically, inhibits their depolymerization. This stabilization disrupts the dynamic equilibrium of the microtubule system, preventing the normal function of the mitotic spindle and arresting cancer cells at the G2/M phase of the cell cycle. Unable to complete division, the cells ultimately undergo apoptosis (programmed cell death).
Compared with paclitaxel, docetaxel has approximately a two-fold greater affinity for the tubulin binding site and achieves higher intracellular concentrations, resulting in a longer duration of action. These pharmacological advantages contribute to docetaxel’s broad spectrum of antitumor activity across several solid tumor types. In addition to its antimicrotubule effects, docetaxel has been shown to induce the phosphorylation and inactivation of the anti-apoptotic protein Bcl-2, further promoting cancer cell death.
Docetaxel Seacross is approved by regulatory authorities worldwide for the treatment of the following cancer types:
- Breast cancer: Docetaxel is used both as adjuvant therapy (after surgery to reduce the risk of cancer recurrence) and for metastatic/locally advanced disease. In the adjuvant setting, it is typically combined with doxorubicin and cyclophosphamide (the TAC regimen) or with cyclophosphamide alone (the TC regimen). The TAX316 trial demonstrated that TAC significantly improved disease-free survival compared with the older FAC regimen. For metastatic breast cancer, docetaxel may be used as monotherapy or in combination with other agents such as trastuzumab (for HER2-positive disease) or capecitabine.
- Non-small cell lung cancer (NSCLC): In the first-line setting, docetaxel is combined with cisplatin for locally advanced or metastatic NSCLC. As second-line therapy after platinum-based chemotherapy failure, docetaxel monotherapy has been shown to improve overall survival compared with best supportive care, as demonstrated in the landmark TAX317 and TAX320 trials. Current NCCN and ESMO guidelines include docetaxel-based regimens among their recommended options for NSCLC.
- Metastatic castration-resistant prostate cancer (mCRPC): Docetaxel combined with prednisone is a standard first-line chemotherapy regimen for mCRPC. The pivotal TAX327 trial demonstrated a significant overall survival benefit for docetaxel every three weeks plus prednisone compared with the previous standard of mitoxantrone plus prednisone. Docetaxel has also shown benefit in the hormone-sensitive metastatic setting (the CHAARTED and STAMPEDE trials), establishing its role earlier in the prostate cancer treatment pathway.
- Gastric adenocarcinoma: Docetaxel is used in combination with cisplatin and 5-fluorouracil (the DCF or TCF regimen) for the treatment of metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, in patients who have not received prior chemotherapy. The V325 trial demonstrated improved response rates, time to progression, and overall survival with this triplet combination.
- Head and neck squamous cell carcinoma: Docetaxel is used as part of induction chemotherapy (cisplatin and 5-fluorouracil, the TPF regimen) before radiotherapy for locally advanced squamous cell carcinoma of the head and neck. The TAX323 and TAX324 trials demonstrated superior progression-free and overall survival with the addition of docetaxel to the PF regimen.
While both docetaxel and paclitaxel are taxanes that stabilize microtubules, they have distinct pharmacological profiles. Docetaxel has approximately twice the binding affinity for tubulin, achieves higher intracellular drug concentrations, and has a longer intracellular retention time. These differences translate into different efficacy and toxicity profiles: docetaxel tends to cause more neutropenia and fluid retention, while paclitaxel is more commonly associated with peripheral neuropathy and hypersensitivity reactions. The choice between the two agents depends on the specific cancer type, treatment protocol, and individual patient factors.
What Should You Know Before Taking Docetaxel Seacross?
Contraindications
There are specific clinical situations in which docetaxel must not be administered. These absolute contraindications must be carefully evaluated by the treating oncologist before initiating therapy.
- Hypersensitivity: Docetaxel must not be given to patients with a known severe hypersensitivity to docetaxel or to polysorbate 80, which is used as an excipient in the formulation. Severe allergic reactions including anaphylaxis have been reported and can be life-threatening.
- Baseline neutropenia: Treatment must not be initiated in patients with a baseline neutrophil count below 1,500 cells/mm³. Neutropenia is the dose-limiting toxicity of docetaxel, and starting treatment with already low neutrophil counts poses an unacceptable risk of severe, potentially fatal infections.
- Severe hepatic impairment: Docetaxel is extensively metabolized in the liver by the CYP3A4 enzyme. Patients with severe liver dysfunction (bilirubin greater than the upper limit of normal, or transaminases greater than 3.5 times the upper limit of normal combined with alkaline phosphatase greater than 6 times the upper limit of normal) are at significantly increased risk of severe toxicity, including toxic death. Docetaxel is contraindicated in these patients.
- Pregnancy and breastfeeding: Docetaxel is embryotoxic and fetotoxic and must not be used during pregnancy. Breastfeeding must be discontinued during treatment.
Warnings and Precautions
All patients must receive oral corticosteroid premedication (typically dexamethasone 16 mg per day, e.g., 8 mg twice daily, for 3 days starting the day before docetaxel infusion) unless contraindicated. This premedication significantly reduces the incidence and severity of fluid retention and the risk of hypersensitivity reactions during infusion. Failure to premedicate appropriately can result in severe, potentially life-threatening complications.
Before and during treatment with docetaxel, your oncology team will carefully monitor you for the following potential complications:
- Hematological toxicity: Neutropenia is the most frequent and dose-limiting side effect. Severe neutropenia (grade 3–4, neutrophils below 500 cells/mm³) occurs in the majority of patients. Febrile neutropenia (fever with severe neutropenia) is a medical emergency requiring hospitalization and broad-spectrum antibiotics. Blood counts must be checked before each treatment cycle. Growth factor support (G-CSF) may be used prophylactically in high-risk patients.
- Hypersensitivity reactions: Severe allergic reactions may occur within minutes of starting the infusion, even in patients who have tolerated previous cycles. Symptoms include hypotension, bronchospasm, generalized rash, and erythema. Patients must be closely monitored during infusion. If a severe reaction occurs, the infusion must be stopped immediately and appropriate treatment administered.
- Fluid retention: Docetaxel causes cumulative fluid retention that manifests as peripheral edema, pleural effusions, pericardial effusions, and ascites. The onset and severity are related to cumulative dose. Corticosteroid premedication significantly delays onset and reduces the incidence. Diuretics may be needed to manage fluid retention.
- Peripheral neuropathy: Sensory neuropathy (numbness, tingling, pain in hands and feet) is common. Motor neuropathy (weakness) is less common but can occur. Symptoms may worsen with continued treatment and may be partially or fully reversible after discontinuation. If severe neuropathy develops, dose reduction or treatment discontinuation may be necessary.
- Skin reactions: Cutaneous toxicity includes localized eruptions on the hands, feet, arms, face, and chest, with or without pruritus. Nail changes (discoloration, onycholysis, pain) are common with repeated cycles. Severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported rarely.
- Hepatic impairment: Patients with elevated liver enzymes are at increased risk of grade 4 toxicity, including toxic death. Liver function tests should be performed before each treatment cycle. Dose reductions are required for mild to moderate hepatic impairment.
- Cardiac toxicity: Cardiac events including heart failure have been reported, particularly in patients receiving docetaxel in combination with trastuzumab or following prior anthracycline therapy. Cardiac function should be monitored in at-risk patients.
- Gastrointestinal toxicity: Nausea, vomiting, diarrhea, and stomatitis (mouth sores) are common. Severe enterocolitis with dehydration and life-threatening gastrointestinal perforation have been reported rarely. Patients should be advised to report severe or persistent gastrointestinal symptoms promptly.
- Pulmonary toxicity: Rare cases of interstitial pneumonia, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS) have been reported. Patients who develop new or worsening respiratory symptoms should be evaluated promptly.
- Secondary malignancies: As with other cytotoxic chemotherapy agents, there is a theoretical risk of secondary malignancies with docetaxel, particularly when combined with other DNA-damaging agents.
Pregnancy and Breastfeeding
Docetaxel is classified as embryotoxic and fetotoxic based on preclinical studies. It must not be used during pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose. If pregnancy occurs during treatment, the patient should be informed of the potential hazard to the fetus and given appropriate genetic counseling.
It is not known whether docetaxel is excreted in human breast milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding must be discontinued during docetaxel treatment and should not be resumed until the drug has been cleared from the body.
Male patients receiving docetaxel should also use effective contraception during and for at least 6 months after treatment. Men are advised to seek counseling on sperm cryopreservation before starting therapy, as docetaxel may impair male fertility.
Docetaxel may cause temporary or permanent impairment of fertility in both men and women. Patients who wish to have children in the future should discuss fertility preservation options (such as sperm banking or egg freezing) with their oncology team before starting treatment.
How Does Docetaxel Seacross Interact with Other Drugs?
Docetaxel is extensively metabolized by the cytochrome P450 3A4 (CYP3A4) isoenzyme in the liver. Any substance that inhibits or induces CYP3A4 activity can significantly alter docetaxel plasma concentrations, potentially leading to increased toxicity or reduced therapeutic efficacy. Pharmacokinetic studies have demonstrated that co-administration of ketoconazole, a potent CYP3A4 inhibitor, reduced docetaxel clearance by approximately 49%, resulting in substantially higher drug exposure. For this reason, concomitant use of potent CYP3A4 inhibitors should be avoided during docetaxel treatment whenever possible.
The clinical significance of these interactions cannot be overstated. Even moderate changes in docetaxel plasma concentrations can tip the balance between therapeutic benefit and unacceptable toxicity, particularly with regard to neutropenia, the drug’s dose-limiting side effect. Patients should provide a complete medication list to their oncology team, including prescription medications, over-the-counter drugs, herbal supplements, and dietary products such as grapefruit juice.
Major Interactions
| Drug/Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Ketoconazole | CYP3A4 inhibitor | Reduces docetaxel clearance by ~49%, significantly increasing toxicity | Avoid concomitant use |
| Itraconazole | CYP3A4 inhibitor | Substantially increases docetaxel exposure and risk of severe neutropenia | Avoid concomitant use |
| Ritonavir / HIV protease inhibitors | Strong CYP3A4 inhibitor | Marked increase in docetaxel levels and risk of life-threatening toxicity | Avoid concomitant use; if unavoidable, significant dose reduction required |
| Rifampicin | CYP3A4 inducer | Reduces docetaxel exposure, potentially reducing anticancer efficacy | Avoid concomitant use |
| Phenytoin / Carbamazepine | CYP3A4 inducer | Accelerates docetaxel metabolism, reducing therapeutic levels | Consider alternative anticonvulsants (e.g., levetiracetam) |
Minor Interactions and Considerations
| Drug/Substance | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Erythromycin / Clarithromycin | Moderate CYP3A4 inhibitor | May moderately increase docetaxel levels | Use with caution; consider alternative antibiotics |
| Ciclosporin | CYP3A4 inhibitor | May increase docetaxel exposure | Monitor closely for increased toxicity |
| Grapefruit / Grapefruit juice | CYP3A4 inhibitor | May increase docetaxel levels | Avoid during treatment |
| St. John’s Wort | CYP3A4 inducer | May decrease docetaxel efficacy | Avoid during treatment |
| Dexamethasone (premedication) | Moderate CYP3A4 inducer | Therapeutic benefit outweighs interaction; premedication is required | Continue as prescribed; essential for safety |
In addition to pharmacokinetic interactions, docetaxel may have pharmacodynamic interactions with other myelosuppressive agents. When used in combination chemotherapy regimens (e.g., with cisplatin, doxorubicin, or cyclophosphamide), the additive bone marrow suppressive effects can increase the risk and severity of neutropenia and other hematological toxicities. These combinations are well-studied, and dosing guidelines account for these additive effects, but close hematological monitoring remains essential.
Patients should also be aware that docetaxel may reduce the effectiveness of live vaccines due to immunosuppression. Live vaccines should be avoided during docetaxel treatment and for a period after treatment completion. Inactivated vaccines may be given but may produce a suboptimal immune response.
What Is the Correct Dosage of Docetaxel Seacross?
Docetaxel dosing is individualized based on the patient’s body surface area (BSA), which is calculated from height and weight. The dose is expressed in milligrams per square meter (mg/m²) to account for the wide variation in patient size and ensure consistent drug exposure. All doses must be calculated, prepared, and administered by qualified healthcare professionals experienced in the use of cytotoxic chemotherapy.
Before each treatment cycle, a complete blood count must be performed to confirm that the neutrophil count is at least 1,500 cells/mm³. If neutrophil counts are insufficient, treatment must be delayed until hematological recovery. Liver function tests should also be evaluated before each cycle, as hepatic impairment significantly increases the risk of severe toxicity.
Adults
| Cancer Type | Dose | Schedule | Combination |
|---|---|---|---|
| Breast cancer (adjuvant) | 75 mg/m² | Every 3 weeks, 6 cycles | With doxorubicin + cyclophosphamide (TAC) |
| Breast cancer (metastatic, monotherapy) | 100 mg/m² | Every 3 weeks | Monotherapy |
| Breast cancer (metastatic, combination) | 75 mg/m² | Every 3 weeks | With capecitabine or trastuzumab |
| NSCLC (first-line) | 75 mg/m² | Every 3 weeks | With cisplatin |
| NSCLC (second-line) | 75 mg/m² | Every 3 weeks | Monotherapy |
| Prostate cancer (mCRPC) | 75 mg/m² | Every 3 weeks | With prednisone/prednisolone 5 mg BID |
| Gastric adenocarcinoma | 75 mg/m² | Every 3 weeks | With cisplatin + 5-fluorouracil (DCF) |
| Head and neck cancer | 75 mg/m² | Every 3 weeks, 4 cycles | With cisplatin + 5-fluorouracil (TPF) |
Children
The safety and efficacy of docetaxel in pediatric patients (children and adolescents under 18 years of age) have not been established. Docetaxel is not indicated for use in children. There are no approved pediatric indications, and the use of docetaxel in this population should only be considered in the context of clinical trials or when no alternative treatments are available, under the guidance of a specialist pediatric oncologist.
Elderly Patients
No specific dose adjustments are recommended based on age alone. However, elderly patients (aged 65 years and older) may be at increased risk of certain toxicities, particularly neutropenia, infections, and fatigue. Clinical trials have included patients up to 75 years of age. Careful assessment of overall fitness, organ function, and comorbidities is essential when making treatment decisions in older patients. The International Society of Geriatric Oncology (SIOG) recommends comprehensive geriatric assessment for elderly patients being considered for taxane-based chemotherapy.
Dose Adjustments
Dose adjustments are frequently required during docetaxel treatment based on the severity of toxicities experienced. The following general principles apply:
- Febrile neutropenia or prolonged grade 4 neutropenia: Reduce dose by 25% (e.g., from 100 mg/m² to 75 mg/m², or from 75 mg/m² to 60 mg/m²). Consider prophylactic G-CSF for subsequent cycles.
- Severe peripheral neuropathy (grade 3 or higher): Discontinue docetaxel treatment.
- Severe skin toxicity: Reduce dose. If severe reactions recur despite dose reduction, discontinue treatment.
- Cumulative fluid retention: If severe edema develops despite corticosteroid premedication, dose reduction or treatment discontinuation may be necessary.
- Hepatic impairment: Patients with mild to moderate elevation of liver enzymes (AST/ALT >1.5 times ULN plus alkaline phosphatase >2.5 times ULN) should not receive docetaxel unless the potential benefit clearly outweighs the risk. If treatment proceeds, dose reductions are mandatory.
Missed Dose
Because docetaxel is administered in a supervised clinical setting on a scheduled basis (typically every 3 weeks), missed doses in the traditional sense are uncommon. However, treatment delays may occur due to insufficient neutrophil recovery, infection, or other toxicities. If a cycle is delayed, the next dose is given as soon as the patient has recovered to an acceptable clinical and hematological status. The treatment interval should not be shortened to make up for a delayed cycle. Your oncology team will determine the optimal timing for resuming treatment.
Overdose
There is no specific antidote for docetaxel overdose. In the event of an overdose, the patient should be monitored closely in a specialized unit with frequent vital signs and blood count assessments. The primary expected complications of overdose are severe bone marrow suppression (particularly neutropenia), peripheral neurotoxicity, and mucositis. Treatment is supportive and symptomatic: prophylactic G-CSF should be given as soon as possible to mitigate severe neutropenia, and patients should receive appropriate supportive care including transfusions, antibiotics, and nutritional support as needed.
What Are the Side Effects of Docetaxel Seacross?
Like all chemotherapy drugs, docetaxel can cause side effects, although not everyone will experience all of them. The frequency and severity of side effects depend on the dose, treatment schedule, whether docetaxel is used as monotherapy or in combination with other drugs, and individual patient factors. Understanding the potential side effects allows patients and caregivers to recognize problems early and seek appropriate medical attention.
Docetaxel side effects are classified by frequency according to the following international convention: very common (affects more than 1 in 10 people), common (affects 1 to 10 in 100 people), uncommon (affects 1 to 10 in 1,000 people), rare (affects 1 to 10 in 10,000 people), and not known (frequency cannot be estimated from available data).
Very Common
Affects more than 1 in 10 patients
- Neutropenia – Low white blood cell count; the most common dose-limiting toxicity. Severe neutropenia (grade 3–4) occurs in up to 75% of patients
- Anemia – Low red blood cell count, causing tiredness and shortness of breath
- Febrile neutropenia – Fever with severe neutropenia, requiring urgent medical attention
- Alopecia – Hair loss, typically complete but reversible after treatment ends
- Nausea and vomiting – Usually manageable with antiemetic medications
- Diarrhea – May range from mild to severe; report persistent diarrhea to your doctor
- Stomatitis/mucositis – Painful inflammation and sores in the mouth and throat
- Fatigue and asthenia – Tiredness and weakness, often cumulative with repeated cycles
- Fluid retention/edema – Swelling, usually in legs and feet; reduced by corticosteroid premedication
- Peripheral neuropathy – Numbness, tingling, or pain in hands and feet
- Skin reactions – Rash, redness, and itching
- Nail changes – Discoloration, loosening (onycholysis), and pain
- Myalgia and arthralgia – Muscle and joint pain
- Infections – Due to immunosuppression from neutropenia
Common
Affects 1 to 10 in 100 patients
- Thrombocytopenia – Low platelet count, increasing bleeding risk
- Constipation – May be exacerbated by antiemetic medications
- Abdominal pain – Report severe or persistent pain immediately
- Taste changes (dysgeusia) – Altered or metallic taste
- Hypersensitivity reactions – Flushing, rash, chest tightness during infusion
- Elevated liver enzymes – Transient increases in AST, ALT, and bilirubin
- Cardiac arrhythmias – Typically mild and transient
- Epistaxis (nosebleeds) – Due to effects on blood cell counts and mucous membranes
- Decreased appetite – May contribute to weight loss during treatment
- Dehydration – Secondary to diarrhea, vomiting, or reduced fluid intake
Uncommon
Affects 1 to 10 in 1,000 patients
- Heart failure – Especially in patients with prior anthracycline exposure
- Gastrointestinal perforation – Requires immediate surgical attention
- Interstitial pneumonia/lung fibrosis – New cough or breathlessness should be reported
- Severe skin reactions (SJS/TEN) – Blistering and widespread skin peeling
- Colitis/enterocolitis – Severe bowel inflammation
- Disseminated intravascular coagulation (DIC) – Serious clotting disorder
Rare
Affects fewer than 1 in 1,000 patients
- Anaphylactic shock – Life-threatening allergic reaction requiring emergency treatment
- Acute respiratory distress syndrome (ARDS) – Severe lung inflammation
- Cystoid macular edema – Visual disturbances due to retinal swelling
- Radiation recall – Skin reaction in previously irradiated areas
- Tumor lysis syndrome – Rapid cancer cell breakdown causing metabolic abnormalities
- Hepatitis – Liver inflammation, occasionally severe
Contact your oncology team or seek emergency medical care immediately if you experience: fever above 38°C (especially if accompanied by chills or sweating, as this may indicate febrile neutropenia), severe or persistent diarrhea or vomiting, signs of serious allergic reaction (difficulty breathing, swelling of face or throat, severe rash), unusual bleeding or bruising, severe mouth sores preventing eating or drinking, signs of infection (persistent sore throat, cough, burning during urination), sudden shortness of breath or chest pain, or severe abdominal pain.
It is important to note that many side effects of docetaxel are manageable with appropriate supportive care and typically resolve after treatment completion. Hair loss, one of the most distressing side effects for many patients, is almost always fully reversible, with hair regrowth typically beginning 2–3 months after the last treatment cycle. Your oncology team can provide medications and strategies to help manage side effects and maintain your quality of life during treatment.
How Should You Store Docetaxel Seacross?
Docetaxel Seacross is a hospital-administered medication, so patients do not typically need to store it at home. However, understanding proper storage conditions is important for ensuring drug integrity and safety. The following storage guidelines apply:
- Temperature: Store below 25°C (77°F). Do not freeze. Freezing can damage the formulation and render it unsuitable for use.
- Light protection: Keep the vials in the original outer packaging to protect from light. Docetaxel is sensitive to light and may degrade if exposed to direct sunlight or strong artificial light for extended periods.
- Packaging: Keep the product in its original carton until time of use. Inspect the vial before use: the solution should be clear and free from visible particles. Do not use if the solution appears cloudy, discolored, or contains particulate matter.
- After dilution: Once diluted for infusion, the solution should be used within 6 hours at room temperature (below 25°C) or within 48 hours if stored in a refrigerator (2–8°C). These stability data are based on in-use studies and include the time of infusion.
- Expiry date: Do not use Docetaxel Seacross after the expiry date stated on the carton and vial label. The expiry date refers to the last day of that month.
- Disposal: Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic drugs. Docetaxel is a cytotoxic agent and must not be disposed of via household waste or wastewater.
Healthcare professionals handling docetaxel should follow standard precautions for the safe handling of cytotoxic agents, including the use of protective gloves, gowns, and closed-system transfer devices where available. Pregnant healthcare workers should not handle cytotoxic drugs. In the event of accidental skin contact, the affected area should be washed immediately and thoroughly with soap and water. If accidental eye contact occurs, rinse immediately with copious amounts of water and seek medical advice.
What Does Docetaxel Seacross Contain?
Docetaxel Seacross is a clear, viscous, yellowish to brownish-yellow concentrate for solution for infusion. Understanding the composition of the product is important both for clinical use and for identifying potential sources of hypersensitivity reactions or other adverse effects related to excipients.
Active Ingredient
The active substance is docetaxel. Each milliliter of concentrate contains 20 mg of docetaxel. Docetaxel is a semisynthetic taxane with the molecular formula C43H53NO14 and a molecular weight of 807.88 g/mol. It is derived from 10-deacetylbaccatin III, a natural precursor extracted from the needles of the European yew tree (Taxus baccata). The semisynthetic process ensures a reliable and sustainable supply of the active compound without requiring the destructive harvesting of slow-growing yew trees.
Excipients
- Polysorbate 80: A non-ionic surfactant used to solubilize docetaxel. Polysorbate 80 has been associated with hypersensitivity reactions in some patients. Patients with a known allergy to polysorbate 80 should not receive Docetaxel Seacross.
- Anhydrous ethanol (ethyl alcohol): Used as a co-solvent to maintain docetaxel in solution. The ethanol content should be considered in patients with alcohol dependence, liver disease, epilepsy, or other conditions where alcohol exposure may be harmful. The ethanol content may also be relevant for patients receiving other medications that interact with alcohol, and for patients who avoid alcohol for religious or personal reasons.
Docetaxel Seacross contains ethanol (alcohol) as an excipient. The amount of ethanol per dose varies based on body surface area and the prescribed dose. At a typical dose of 75 mg/m² for an average adult, the ethanol content is approximately 1.5–2 grams per infusion. While this amount is relatively small, it may be clinically relevant for certain patient populations. Patients should inform their healthcare team if they have concerns about ethanol exposure. The ethanol content may also affect driving ability and the use of machinery for a short period after infusion.
Available Presentations
Docetaxel Seacross 20 mg/ml concentrate for solution for infusion is available in glass vials containing different volumes of concentrate. Common vial sizes include 1 ml (containing 20 mg docetaxel), 4 ml (containing 80 mg docetaxel), and 8 ml (containing 160 mg docetaxel). The required number of vials and volume are determined by the calculated dose based on the patient’s body surface area. The concentrate must be diluted before infusion in 0.9% sodium chloride solution or 5% glucose solution to a final concentration of 0.3–0.74 mg/ml.
Frequently Asked Questions
Docetaxel Seacross and Taxotere both contain the same active ingredient, docetaxel. Taxotere is the original branded formulation developed by Sanofi, while Docetaxel Seacross is a generic equivalent. Both products meet the same stringent regulatory standards for quality, safety, and efficacy. The clinical outcomes, side effect profile, and dosing regimens are the same for both products. The choice between branded and generic docetaxel is typically determined by institutional formulary decisions and availability.
The duration of docetaxel treatment varies depending on the cancer type and treatment goal. For adjuvant breast cancer treatment (TAC regimen), 6 cycles are typically given over approximately 18 weeks. For head and neck cancer induction (TPF), 4 cycles are standard. For metastatic cancers, treatment may continue for as long as it is providing benefit and the patient is tolerating it, typically assessed every 2–3 cycles with imaging scans. Your oncologist will discuss the planned treatment duration with you and adjust based on your response and tolerance.
Yes, hair loss (alopecia) from docetaxel is almost always reversible. Hair typically begins to regrow 2–3 months after the last treatment cycle. Initially, the new hair may have a different texture or color than before treatment, but it usually returns to its pre-treatment state over time. Complete hair regrowth generally occurs within 6–12 months after treatment completion. Scalp cooling (cold cap therapy) during infusion may help reduce hair loss for some patients, though effectiveness varies.
Docetaxel may affect your ability to drive or operate machinery due to side effects such as fatigue, dizziness, and the ethanol content in the formulation. On infusion days, it is generally advisable to avoid driving and have someone accompany you to and from the treatment center. Between treatment cycles, your ability to drive depends on how you are feeling. If you experience significant fatigue, neuropathy affecting coordination, or other symptoms that could impair driving, you should refrain from driving and discuss this with your oncology team.
Fever during docetaxel treatment must be taken very seriously, as it may indicate febrile neutropenia – a potentially life-threatening condition where fever occurs alongside severely low white blood cell counts. If your temperature reaches 38°C (100.4°F) or above, contact your oncology team immediately, regardless of the time of day. Do not wait to see if the fever resolves on its own. You may need to be evaluated urgently with blood tests and possibly hospitalized for intravenous antibiotics. Keep a thermometer at home and monitor your temperature regularly, especially 7–14 days after each treatment cycle when neutrophil counts are typically at their lowest.
All information in this article is based on internationally recognized medical sources, including: the European Medicines Agency (EMA) Summary of Product Characteristics for docetaxel, the U.S. Food and Drug Administration (FDA) prescribing information, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, the European Society for Medical Oncology (ESMO) guidelines, and peer-reviewed publications from high-impact oncology journals. All medical claims adhere to evidence level 1A, the highest quality of evidence based on systematic reviews and meta-analyses of randomized controlled trials.
References
- European Medicines Agency (EMA). Docetaxel – Summary of Product Characteristics. Accessed December 2025.
- U.S. Food and Drug Administration (FDA). Docetaxel (Taxotere) Prescribing Information. Revised 2024.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer (Version 2.2025). Plymouth Meeting, PA: NCCN; 2025.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 3.2025). Plymouth Meeting, PA: NCCN; 2025.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 1.2025). Plymouth Meeting, PA: NCCN; 2025.
- Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-1220.
- Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer (TAX316). N Engl J Med. 2005;352(22):2302-2313.
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (TAX327). N Engl J Med. 2004;351(15):1502-1512.
- Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103.
- Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (TAX323). N Engl J Med. 2007;357(17):1695-1704.
- Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd list. Geneva: WHO; 2023.
- British National Formulary (BNF). Docetaxel Monograph. National Institute for Health and Care Excellence (NICE). 2025.
Editorial Team
Medical Content
Written by licensed specialist physicians with expertise in oncology and clinical pharmacology
Medical Review
Reviewed by iMedic Medical Review Board following GRADE evidence framework and international guidelines
Evidence Standard
Level 1A evidence from systematic reviews, meta-analyses, and randomized controlled trials
Editorial Policy
Independent medical content with no commercial funding or pharmaceutical sponsorship
All content follows the iMedic Editorial Standards and is regularly updated to reflect the latest clinical evidence and guideline recommendations. For more information about our medical team, visit our Medical Team page.